Nvidia Options Price in $280 Billion Earnings Swing 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Trump Buys SpaceX Shares After Record IPO 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Add as a preferred source on Google
REDWOOD CITY, Calif., May 03, 2018 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report first quarter 2018 financial results after market close on Thursday, May 10, 2018. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.
| Live Call: | U.S. | 855 890 8665 | |
| International | 720 634 2938 | ||
| Passcode | 9585106 | ||
| Live Webcast: | Codexis IR Website | ||
| The webcast will be archived for 30 days. | |||
| Replay: | U.S. | 855 859 2056 | |
| International | 404 537 3406 | ||
| Passcode | 9585106 | ||
| The replay will be available for 48 hours | |||
About Codexis, Inc.
Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see www.codexis.com.
CONTACTS
Investors
LHA Investor Relations
Jody Cain, 310 691 7100
[email protected]
